Articles
5 June 2009
Vol. 1 No. 11: Thalidomide in the treatment of multiple myeloma, Sydney, 10 April 2005
https://doi.org/10.4081/hmr.v1i11.350

Thalidomide alone or in combination: results in refractory patients

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
235
Views
364
Downloads

Authors

Jesús F. San Miguel
support@pagepress.org
Thalidomide was first marketed in the 1950s for the treatment of pregnancy-related morning sickness and later as a sedative, but was withdrawn because of serious adverse events in pregnant women including teratogenicity and dysmelia.1 Interest in the drug resurfaced in the 1990s because of its antiangiogenic and immunomodulatory effects.2 Recently thalidomide has been used to treat multiple myeloma (MM) either alone or in combination with other therapies. This review summarizes study results of thalidomide treatment in patients who have not benefited from conventional therapy.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Thalidomide alone or in combination: results in refractory patients. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 1(11). https://doi.org/10.4081/hmr.v1i11.350